Human Epidermal Growth Factor Receptor targeted inhibitors for the treatment of ovarian cancer

Maria Bonello, Andrew Sims, Simon Langdon

Research output: Contribution to journalArticlepeer-review

Abstract

Ovarian cancer is the second most lethal gynecological cancer worldwide and while most patients respond to initial therapy, they often relapse with resistant disease. Human epidermal growth factor receptors (especially HER1/EGFR and HER2/ERBB2) are involved in disease progression, hence strategies to inhibit their action could prove advantageous in ovarian cancer patients, especially patients resistant to first line therapy. Monoclonal antibodies and tyrosine kinase inhibitors are two drug classes which act on these receptors. They have demonstrated valuable antitumor activity in multiple cancer types, and their possible use in ovarian cancer continues to be studied. In this review, we 1) discuss the human epidermal growth factor receptor family; 2) review emerging clinical studies on monoclonal antibodies and tyrosine kinase inhibitors targeting these receptors in ovarian cancer patients; 3) propose future research possibilities in this research area.
Original languageEnglish
JournalCancer Biology and Medicine
Volume15
Issue number4
DOIs
Publication statusPublished - 15 Nov 2018

Fingerprint

Dive into the research topics of 'Human Epidermal Growth Factor Receptor targeted inhibitors for the treatment of ovarian cancer'. Together they form a unique fingerprint.

Cite this